Somebody said...A new drug, darolutamide, a second-generation androgen receptor (AR) inhibitor, may soon be a new treatment option for patients with non-metastatic castration-resistant prostate cancer (nmCRPC).Patients with metastatic “hormone-sensitive” prostate cancer (mHSPC) may soon have another option to slow the growth of their cancer. PCF Young Investigator Dr. Andrew Armstrong of the Duke University School of Medicine and Duke Cancer Institute presented results showing that the addition of enzalutamide to ADT reduced the chances of tumor growth on scans or death (whichever came first) by 61% compared with a placebo, i
InTheShop said...that's all I need to know - going to be a miracle cure ...